FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140816451> ?p ?o ?g. }

• W2140816451 endingPage "855" @default.
• W2140816451 startingPage "852" @default.
• W2140816451 abstract "The outcome of systemic sclerosis (SSc) has become more favorable during the past years. Respiratory failure or renal crisis became less frequent, therefore more attention should be paid to long-term comorbidities, such as malignancies secondary to scleroderma. The incidence of malignant lymphoproliferative diseases, as well as that of solid tumors are higher in a number of rheumatic diseases including SSc. Some cytotoxic agents, primarily cyclophosphamide used in the treatment of SSc, as well as exposure to chemicals or smoking may further increase cancer risk. We also present malignancies in 218 scleroderma patients undergoing follow-up in our department were assessed for secondary malignancies. Although the number of SSc patients with tumor is relatively small, we compared our cohort to the Health for All Hungarian database and calculated standard incidence ratios (SIR). We identified 11 cases of malignancy in 10 SSc patients (4.6%). One patient had two types of tumor: breast cancer before the onset of SSc and later malignant lymphoma. Half of SSc patients with cancer belonged to the diffuse cutaneous (dcSSc) subtype. The mean age at onset of SSc was 54.6 years, while that at the diagnosis of malignancy was 61.5 years. The mean disease duration of scleroderma at the time of cancer diagnosis was 6.6 years. Five patients died, 4 due to the underlying malignancy. Among the five surviving patients, the mean survival time was 4.9 years. Altogether 3 patients had non-Hodgkin's lymphoma, 2 had bronchial cancer, 2 had breast cancer, one had leiomyosarcoma of the leg, one had esophageal cancer, one had cervix cancer and one had skin cancer. In comparison to the Health for All database, the overall SIR of all malignancies in SSc was 1.07 (CI: 0.82–1.38) varying between 5.8 and 52.4 in different tumor types. Only one cancer patient received cyclophosphamide therapy. In conclusion, secondary tumors including lung, skin and breast cancer, as well as lymphomas are more common in SSc than in the general population. The adequate treatment and follow-up of scleroderma patients may help us to lower the risk of malignancies secondary to SSc." @default.
• W2140816451 created "2016-06-24" @default.
• W2140816451 creator A5020937342 @default.
• W2140816451 creator A5029915112 @default.
• W2140816451 creator A5029969068 @default.
• W2140816451 creator A5036276929 @default.
• W2140816451 creator A5054873598 @default.
• W2140816451 creator A5059786438 @default.
• W2140816451 creator A5078842176 @default.
• W2140816451 creator A5080175283 @default.
• W2140816451 date "2012-10-01" @default.
• W2140816451 modified "2023-10-17" @default.
• W2140816451 title "Malignancies associated with systemic sclerosis" @default.
• W2140816451 cites W1964592252 @default.
• W2140816451 cites W1977065417 @default.
• W2140816451 cites W1993700004 @default.
• W2140816451 cites W1993747076 @default.
• W2140816451 cites W1995049935 @default.
• W2140816451 cites W2005097349 @default.
• W2140816451 cites W2011173994 @default.
• W2140816451 cites W2023946136 @default.
• W2140816451 cites W2026886918 @default.
• W2140816451 cites W2028921539 @default.
• W2140816451 cites W2044693321 @default.
• W2140816451 cites W2047143899 @default.
• W2140816451 cites W2050182784 @default.
• W2140816451 cites W2071216920 @default.
• W2140816451 cites W2076796605 @default.
• W2140816451 cites W2080372545 @default.
• W2140816451 cites W2084554507 @default.
• W2140816451 cites W2091579544 @default.
• W2140816451 cites W2092903695 @default.
• W2140816451 cites W2095753106 @default.
• W2140816451 cites W2106249804 @default.
• W2140816451 cites W2113150329 @default.
• W2140816451 cites W2126366282 @default.
• W2140816451 cites W2133103918 @default.
• W2140816451 cites W2137412705 @default.
• W2140816451 cites W2139634169 @default.
• W2140816451 cites W2140950416 @default.
• W2140816451 cites W2158911776 @default.
• W2140816451 cites W2171875742 @default.
• W2140816451 cites W2620125818 @default.
• W2140816451 cites W4069880 @default.
• W2140816451 doi "https://doi.org/10.1016/j.autrev.2012.02.021" @default.
• W2140816451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22410174" @default.
• W2140816451 hasPublicationYear "2012" @default.
• W2140816451 type Work @default.
• W2140816451 sameAs 2140816451 @default.
• W2140816451 citedByCount "47" @default.
• W2140816451 countsByYear W21408164512012 @default.
• W2140816451 countsByYear W21408164512013 @default.
• W2140816451 countsByYear W21408164512014 @default.
• W2140816451 countsByYear W21408164512015 @default.
• W2140816451 countsByYear W21408164512016 @default.
• W2140816451 countsByYear W21408164512017 @default.
• W2140816451 countsByYear W21408164512018 @default.
• W2140816451 countsByYear W21408164512019 @default.
• W2140816451 countsByYear W21408164512020 @default.
• W2140816451 countsByYear W21408164512021 @default.
• W2140816451 countsByYear W21408164512022 @default.
• W2140816451 countsByYear W21408164512023 @default.
• W2140816451 crossrefType "journal-article" @default.
• W2140816451 hasAuthorship W2140816451A5020937342 @default.
• W2140816451 hasAuthorship W2140816451A5029915112 @default.
• W2140816451 hasAuthorship W2140816451A5029969068 @default.
• W2140816451 hasAuthorship W2140816451A5036276929 @default.
• W2140816451 hasAuthorship W2140816451A5054873598 @default.
• W2140816451 hasAuthorship W2140816451A5059786438 @default.
• W2140816451 hasAuthorship W2140816451A5078842176 @default.
• W2140816451 hasAuthorship W2140816451A5080175283 @default.
• W2140816451 hasConcept C120665830 @default.
• W2140816451 hasConcept C121332964 @default.
• W2140816451 hasConcept C121608353 @default.
• W2140816451 hasConcept C126322002 @default.
• W2140816451 hasConcept C142724271 @default.
• W2140816451 hasConcept C143998085 @default.
• W2140816451 hasConcept C180032290 @default.
• W2140816451 hasConcept C2776256026 @default.
• W2140816451 hasConcept C2776694085 @default.
• W2140816451 hasConcept C2776755627 @default.
• W2140816451 hasConcept C2779134260 @default.
• W2140816451 hasConcept C2779338263 @default.
• W2140816451 hasConcept C2779399171 @default.
• W2140816451 hasConcept C2779625490 @default.
• W2140816451 hasConcept C2779967694 @default.
• W2140816451 hasConcept C530470458 @default.
• W2140816451 hasConcept C61511704 @default.
• W2140816451 hasConcept C71924100 @default.
• W2140816451 hasConcept C72563966 @default.
• W2140816451 hasConceptScore W2140816451C120665830 @default.
• W2140816451 hasConceptScore W2140816451C121332964 @default.
• W2140816451 hasConceptScore W2140816451C121608353 @default.
• W2140816451 hasConceptScore W2140816451C126322002 @default.
• W2140816451 hasConceptScore W2140816451C142724271 @default.
• W2140816451 hasConceptScore W2140816451C143998085 @default.
• W2140816451 hasConceptScore W2140816451C180032290 @default.
• W2140816451 hasConceptScore W2140816451C2776256026 @default.

• next